Ocuphire Pharma Investor Update

RM 26 Summary of Positive MIRA-3 Phase 3 Results for Nyxol Eye Drops Confirms Prior Phase 3 Study Showing Substantial Benefit in Accelerating Reversal of Mydriasis ● ● ● ● ● Met primary endpoint at 90 minutes with 58% of subjects returning to pre-dilation pupil diameter vs. 6% of placebo treated subjects (p < 0.0001) Saving of ~4 hours in time to return to normal pupil diameter Met key secondary endpoints with high statistical significance Efficacy seen at all timepoints from 60 minutes to 24 hours Similar efficacy for one drop and two drops Efficacy across all 3 mydriatic agents - phenylephrine, tropicamide, and ParemydⓇ Efficacy in both light and dark iris colors Accelerated return to normal distance-corrected near visual acuity - Favorable safety and tolerability profile No serious AEs, no drop-outs from AEs No systemic or ocular AEs were observed in ≥ 5% of subjects, except for 11% mild, transient conjunctival hyperemia NDA planned for late 2022 MIRA-3 Topline Reports Ocuphire PHARMA

View entire presentation